Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Switzerland | Healthcare | Pharmaceuticals | CHF 696.28B | 111.8x | 8.66 | CHF 750 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Switzerland | Healthcare | Pharmaceuticals | CHF 215.82B | 21.5x | -6.19 | CHF 267.50 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Roche Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 215.82B | 20.1x | -6.19 | CHF 286.20 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.8% Downside | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 198.49B | 14.7x | 0.2 | CHF 98.44 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.5% Upside | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 198.49B | 14.7x | 0.2 | CHF 98.53 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | Switzerland | Healthcare | Pharmaceuticals | CHF 14.95B | -2,379.2x | 22.01 | CHF 34.66 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Siegfried Holding Ltd | Switzerland | Healthcare | Pharmaceuticals | CHF 4.98B | 38.7x | -2.7 | CHF 1,166 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.2% Downside | Upgrade to Pro+ | |
Galenica Sante | Switzerland | Healthcare | Pharmaceuticals | CHF 3.63B | 20.5x | -0.64 | CHF 73.05 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.1% Upside | Upgrade to Pro+ | |
Dottikon Es Holding AG | Switzerland | Healthcare | Pharmaceuticals | CHF 3.36B | 41.8x | -5.14 | CHF 244 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Joincare Pharmaceutical DRC | Switzerland | Healthcare | Pharmaceuticals | CHF 2.29B | 13.4x | -2.09 | CHF 7.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
COSMO Pharma | Switzerland | Healthcare | Pharmaceuticals | CHF 1.24B | 19.2x | 0.04 | CHF 78.30 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | |
PolyPeptide Group AG | Switzerland | Healthcare | Pharmaceuticals | CHF 1.05B | -41.6x | -1.9 | CHF 31.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.7% Downside | Upgrade to Pro+ | |
Newron Pharmaceuticals | Switzerland | Healthcare | Pharmaceuticals | CHF 158.95M | -9x | -1.39 | CHF 7.71 | -7.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Santhera Pharmaceuticals Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 113.92M | 1.6x | 0.01 | CHF 9.36 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Spexis | Switzerland | Healthcare | Pharmaceuticals | CHF 3.02M | -0.1x | -0.05 | CHF 0.04 | -33.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |